Pharmacokinetics of intravenous trovafloxacin in critically ill adults

Keith M. Olsen, Jill A. Rebuck, Tavis Weidenbach, Douglas N. Fish

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The pharmacokinetic disposition of numerous antimicrobial agents is altered in critically ill patients. Pharmacokinetics of trovafloxacin, a fluoroquinolone indicated specifically for severe, life-threatening infections in the intensive care unit, have not been well studied in this population. We characterized the pharmacokinetic disposition of trovafloxacin after administration of alatrofloxacin, the intravenous prodrug, in critically ill adults. Seven patients (3 men, 4 women; mean ± SD age 59.4 ± 20.6 yrs; baseline aspartate aminotransferase [AST]/alanine aminotransferase [ALT] 66.0 ± 40.6/51.5 ± 37.5 IU/L; median Acute Physiology and Chronic Health Evaluation [APACHE II] score 27, range 15-32) were studied at estimated steady state. Calculated (mean ± SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 ± 1.8 hours, 161.3 ± 41.1 ml/minute, and 1.4 ± 0.4 L/kg. In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 ± 0.5 mg/L, 0.6 ± 0.3 mg/L, and 34.2 ± 10.6 mg·hr/L, respectively. These results are consistent with published values in other patient populations, indicating that trovafloxacin pharmacokinetics are not substantially altered in critically ill patients with normal or mildly impaired hepatic function.

Original languageEnglish (US)
Pages (from-to)400-404
Number of pages5
JournalPharmacotherapy
Volume20
Issue number4
DOIs
StatePublished - Jan 1 2000

Fingerprint

Critical Illness
Pharmacokinetics
APACHE
Fluoroquinolones
Prodrugs
Aspartate Aminotransferases
Anti-Infective Agents
Alanine Transaminase
Intravenous Administration
Population
Area Under Curve
Intensive Care Units
Half-Life
trovafloxacin
Liver
Infection

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Olsen, K. M., Rebuck, J. A., Weidenbach, T., & Fish, D. N. (2000). Pharmacokinetics of intravenous trovafloxacin in critically ill adults. Pharmacotherapy, 20(4), 400-404. https://doi.org/10.1592/phco.20.5.400.35056

Pharmacokinetics of intravenous trovafloxacin in critically ill adults. / Olsen, Keith M.; Rebuck, Jill A.; Weidenbach, Tavis; Fish, Douglas N.

In: Pharmacotherapy, Vol. 20, No. 4, 01.01.2000, p. 400-404.

Research output: Contribution to journalArticle

Olsen, KM, Rebuck, JA, Weidenbach, T & Fish, DN 2000, 'Pharmacokinetics of intravenous trovafloxacin in critically ill adults', Pharmacotherapy, vol. 20, no. 4, pp. 400-404. https://doi.org/10.1592/phco.20.5.400.35056
Olsen, Keith M. ; Rebuck, Jill A. ; Weidenbach, Tavis ; Fish, Douglas N. / Pharmacokinetics of intravenous trovafloxacin in critically ill adults. In: Pharmacotherapy. 2000 ; Vol. 20, No. 4. pp. 400-404.
@article{dd8a3ffcdcce44da8b1a68ee32821b67,
title = "Pharmacokinetics of intravenous trovafloxacin in critically ill adults",
abstract = "The pharmacokinetic disposition of numerous antimicrobial agents is altered in critically ill patients. Pharmacokinetics of trovafloxacin, a fluoroquinolone indicated specifically for severe, life-threatening infections in the intensive care unit, have not been well studied in this population. We characterized the pharmacokinetic disposition of trovafloxacin after administration of alatrofloxacin, the intravenous prodrug, in critically ill adults. Seven patients (3 men, 4 women; mean ± SD age 59.4 ± 20.6 yrs; baseline aspartate aminotransferase [AST]/alanine aminotransferase [ALT] 66.0 ± 40.6/51.5 ± 37.5 IU/L; median Acute Physiology and Chronic Health Evaluation [APACHE II] score 27, range 15-32) were studied at estimated steady state. Calculated (mean ± SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 ± 1.8 hours, 161.3 ± 41.1 ml/minute, and 1.4 ± 0.4 L/kg. In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 ± 0.5 mg/L, 0.6 ± 0.3 mg/L, and 34.2 ± 10.6 mg·hr/L, respectively. These results are consistent with published values in other patient populations, indicating that trovafloxacin pharmacokinetics are not substantially altered in critically ill patients with normal or mildly impaired hepatic function.",
author = "Olsen, {Keith M.} and Rebuck, {Jill A.} and Tavis Weidenbach and Fish, {Douglas N.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1592/phco.20.5.400.35056",
language = "English (US)",
volume = "20",
pages = "400--404",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Pharmacokinetics of intravenous trovafloxacin in critically ill adults

AU - Olsen, Keith M.

AU - Rebuck, Jill A.

AU - Weidenbach, Tavis

AU - Fish, Douglas N.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The pharmacokinetic disposition of numerous antimicrobial agents is altered in critically ill patients. Pharmacokinetics of trovafloxacin, a fluoroquinolone indicated specifically for severe, life-threatening infections in the intensive care unit, have not been well studied in this population. We characterized the pharmacokinetic disposition of trovafloxacin after administration of alatrofloxacin, the intravenous prodrug, in critically ill adults. Seven patients (3 men, 4 women; mean ± SD age 59.4 ± 20.6 yrs; baseline aspartate aminotransferase [AST]/alanine aminotransferase [ALT] 66.0 ± 40.6/51.5 ± 37.5 IU/L; median Acute Physiology and Chronic Health Evaluation [APACHE II] score 27, range 15-32) were studied at estimated steady state. Calculated (mean ± SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 ± 1.8 hours, 161.3 ± 41.1 ml/minute, and 1.4 ± 0.4 L/kg. In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 ± 0.5 mg/L, 0.6 ± 0.3 mg/L, and 34.2 ± 10.6 mg·hr/L, respectively. These results are consistent with published values in other patient populations, indicating that trovafloxacin pharmacokinetics are not substantially altered in critically ill patients with normal or mildly impaired hepatic function.

AB - The pharmacokinetic disposition of numerous antimicrobial agents is altered in critically ill patients. Pharmacokinetics of trovafloxacin, a fluoroquinolone indicated specifically for severe, life-threatening infections in the intensive care unit, have not been well studied in this population. We characterized the pharmacokinetic disposition of trovafloxacin after administration of alatrofloxacin, the intravenous prodrug, in critically ill adults. Seven patients (3 men, 4 women; mean ± SD age 59.4 ± 20.6 yrs; baseline aspartate aminotransferase [AST]/alanine aminotransferase [ALT] 66.0 ± 40.6/51.5 ± 37.5 IU/L; median Acute Physiology and Chronic Health Evaluation [APACHE II] score 27, range 15-32) were studied at estimated steady state. Calculated (mean ± SD) half-life, clearance at steady state, and volume of distribution in all patients were 10.9 ± 1.8 hours, 161.3 ± 41.1 ml/minute, and 1.4 ± 0.4 L/kg. In patients receiving 300 mg, maximum concentration, minimum concentration, and area under the curve from 0-24 hours were 3.6 ± 0.5 mg/L, 0.6 ± 0.3 mg/L, and 34.2 ± 10.6 mg·hr/L, respectively. These results are consistent with published values in other patient populations, indicating that trovafloxacin pharmacokinetics are not substantially altered in critically ill patients with normal or mildly impaired hepatic function.

UR - http://www.scopus.com/inward/record.url?scp=0034127145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034127145&partnerID=8YFLogxK

U2 - 10.1592/phco.20.5.400.35056

DO - 10.1592/phco.20.5.400.35056

M3 - Article

C2 - 10772370

AN - SCOPUS:0034127145

VL - 20

SP - 400

EP - 404

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 4

ER -